Insmed Shares Rise After Raising FY26 Guidance for Products

Dow Jones08-06

Shares of Insmed rose after the biopharmaceutical company raised its full-year revenue guidance for its products as its second-quarter loss narrowed and revenue jumped.

The stock was 34% to $132.91 in recent trading, but has fallen 24% since the start of the year.

The company posted a net loss of $13.2 million, or six cents a share, compared with a loss of $321.7 million, or $1.70 a share, a year earlier.

Revenue nearly quadrupled to $425.5 million. Analysts polled by FactSet expected $393.7 million.

Chief Executive Will Lewis said the U.S. Brinsupri launch has been met with significant enthusiasm and the company reported positive data from its ongoing open-label extension study of TPIP in PAH.

The company raised its fiscal 2026 Brinsupri guidance to between $1.25 billion and $1.4 billion from its previous guidance of at least $1 billion. The company also raised its peak revenue estimate for TPIP to more than $6 billion.

At the request of the copyright holder, you need to log in to view this content

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2657630088?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-08-06 22:34","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2657630088","market":"fut","top_or_hot":-1,"title":"Insmed Shares Rise After Raising FY26 Guidance for Products","media":"Dow Jones","content":"<font class=\"NormalMinus1\" face=\"Arial\">\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  Shares of <a href=\"https://laohu8.com/S/INSM\">Insmed</a> rose after the biopharmaceutical company raised its full-year revenue guidance for its products as its second-quarter loss narrowed and revenue jumped. \n</p>\n<p>\n  The stock was 34% to $132.91 in recent trading, but has fallen 24% since the start of the year. \n</p>\n<p>\n  The company posted a net loss of $13.2 million, or six cents a share, compared with a loss of $321.7 million, or $1.70 a share, a year earlier. \n</p>\n<p>\n  Revenue nearly quadrupled to $425.5 million. Analysts polled by FactSet expected $393.7 million. \n</p>\n<p>\n  Chief Executive Will Lewis said the U.S. Brinsupri launch has been met with significant enthusiasm and the company reported positive data from its ongoing open-label extension study of TPIP in PAH. \n</p>\n<p>\n  The company raised its fiscal 2026 Brinsupri guidance to between $1.25 billion and $1.4 billion from its previous guidance of at least $1 billion. The company also raised its peak revenue estimate for TPIP to more than $6 billion. \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<pre style=\"white-space: pre\">\n \n</pre>\n</font>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Insmed Shares Rise After Raising FY26 Guidance for Products</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nInsmed Shares Rise After Raising FY26 Guidance for Products\n</h2>\n\n<h4 class=\"meta\">\n\n\n<div class=\"head\" \">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Dow Jones </p>\n<p class=\"h-time\">2026-08-06 22:34</p>\n</div>\n\n</div>\n\n\n</h4>\n\n</header>\n<article>\n<font class=\"NormalMinus1\" face=\"Arial\">\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  Shares of <a href=\"https://laohu8.com/S/INSM\">Insmed</a> rose after the biopharmaceutical company raised its full-year revenue guidance for its products as its second-quarter loss narrowed and revenue jumped. \n</p>\n<p>\n  The stock was 34% to $132.91 in recent trading, but has fallen 24% since the start of the year. \n</p>\n<p>\n  The company posted a net loss of $13.2 million, or six cents a share, compared with a loss of $321.7 million, or $1.70 a share, a year earlier. \n</p>\n<p>\n  Revenue nearly quadrupled to $425.5 million. Analysts polled by FactSet expected $393.7 million. \n</p>\n<p>\n  Chief Executive Will Lewis said the U.S. Brinsupri launch has been met with significant enthusiasm and the company reported positive data from its ongoing open-label extension study of TPIP in PAH. \n</p>\n<p>\n  The company raised its fiscal 2026 Brinsupri guidance to between $1.25 billion and $1.4 billion from its previous guidance of at least $1 billion. The company also raised its peak revenue estimate for TPIP to more than $6 billion. \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<pre style=\"white-space: pre\">\n \n</pre>\n</font>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"LU0320765992.SGD","symbol_name":"FTIF - Franklin Biotechnology Discovery A Acc SGD","start_time":0,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","article_id":"2657630088","we_media_id":"106","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2657630088","pubTimestamp":1786026840,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Dow Jones","introduction":"Dow Jones publishes the world’s most trusted business news and financial information in a variety of media.","home_visible":0,"id":"106","head_image":"https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99"},"summary":"Shares of Insmed rose after the biopharmaceutical company raised its full-year revenue guidance for its products as its second-quarter loss narrowed and revenue jumped.The stock was 34% to $132.91 in recent trading, but has fallen 24% since the start of the year.The company posted a net loss of $13.2 million, or six cents a share, compared with a loss of $321.7 million, or $1.70 a share, a year earlier.Revenue nearly quadrupled to $425.5 million. Analysts polled by FactSet expected $393.7 million.Chief Executive Will Lewis said the U.S. Brinsupri launch has been met with significant enthusiasm and the company reported positive data from its ongoing open-label extension study of TPIP in PAH.The company raised its fiscal 2026 Brinsupri guidance to between $1.25 billion and $1.4 billion from its previous guidance of at least $1 billion. The company also raised its peak revenue estimate for TPIP to more than $6 billion.","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"LU0320765992.SGD":"FTIF - Franklin Biotechnology Discovery A Acc SGD","BK4139":"生物科技","LU0889565916.HKD":"FRANKLIN BIOTECHNOLOGY DISCOVERY \"A\" (HKD) ACC","LU0053671581.USD":"摩根大通美国小盘成长股 A(dist)","LU0109394709.USD":"富兰克林生物科技新领域基金A (acc)","INSM":"Insmed"},"translate_title":"Insmed 上调 26 财年产品指引后股价上涨","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"INSM":1.5},"content_text":"Shares of Insmed rose after the biopharmaceutical company raised its full-year revenue guidance for its products as its second-quarter loss narrowed and revenue jumped. \n\n\n  The stock was 34% to $132.91 in recent trading, but has fallen 24% since the start of the year. \n\n\n  The company posted a net loss of $13.2 million, or six cents a share, compared with a loss of $321.7 million, or $1.70 a share, a year earlier. \n\n\n  Revenue nearly quadrupled to $425.5 million. Analysts polled by FactSet expected $393.7 million. \n\n\n  Chief Executive Will Lewis said the U.S. Brinsupri launch has been met with significant enthusiasm and the company reported positive data from its ongoing open-label extension study of TPIP in PAH. \n\n\n  The company raised its fiscal 2026 Brinsupri guidance to between $1.25 billion and $1.4 billion from its previous guidance of at least $1 billion. The company also raised its peak revenue estimate for TPIP to more than $6 billion.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":true,"editions":null,"column":"","sentiment":"1","news_tag":"dataReport","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":true,"need_login_tip":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"isLaohu8Offline":false,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.47.1","shortVersion":"4.47.1","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2657630088","isCrawlerRequest":true}